U.S. drugmakers are rapidly shifting the front end of America’s pharmaceutical ecosystem (e.g. discovery, early-stage-development, and the IP engine) to China through a surge of licensing deals and cross-border partnerships.
AGOA, first enacted in 2000, provides qualifying sub-Saharan African nations with tariff-free access to the U.S. market for thousands of products and was intended to support economic development, democratic reform, and stronger geopolitical ties to the United States.
The October trade deficit fell by 39% for goods and services combined, but even the goods deficit fell to monthly numbers not seen in at least five years. The October deficit in goods was $59.14 billion, down 24.5% from September, the Bureau of Economic Analysis said on Thursday.
The United States is facing a new form of strategic dependence: Chinese-linked firms are reentering critical American industries through influence and control rather than visible ownership.
China’s foray into the automotive industry makes perfect sense for any serious, powerful economy. Every major economic power has its own car brands. China has them now, in droves.
The U.S. goods deficit with China fell by roughly $2 billion in September, coming in at $15.03 billion. China has dropped to fourth place in terms of the countries in which the U.S. has its biggest goods gap.
China is beating the U.S. to the Moon, namely the dark side of the Moon we never see from Earth. It’s colder there. And darker. And China has the energy technologies they’ve invented themselves to make machines work there. We do not.
To trade away aluminum and steel workers’ home market in exchange for padding Big Tech’s bottom line overseas is immoral and wrong. The Section 232 actions on aluminum and steel should be singularly focused on rebuilding domestic output across the supply chains, not used as leverage to help Google and Meta become even more profitable.
The America First Investment Policy rightly seeks to ensure that Wall Street can no longer channel hundreds of billions of U.S. dollars into companies that build China’s military, commit human rights atrocities, and threaten our national security. CPA strongly supports Chairman Moolenaar’s effort to codify this policy into law.
The Senate Special Committee on Aging was back at it this week discussing the woeful predicament of the domestic generic drug industry and its import-facing supply chain. This time, the Committee heard from four generic drug makers opposed to advocacy groups and Washington think tanks.
